Workflow
WHOLE SHINE MEDICAL(002622)
icon
Search documents
关于对皓宸医疗公司的关注函
2023-08-09 01:17
深 圳 证 券 交 易 所 关于对皓宸医疗科技股份有限公司的关注函 公司部关注函〔2023〕第 295 号 皓宸医疗科技股份有限公司董事会: 2023 年 8 月 8 日,你公司披露的《关于公司控制权可能发 生变更的进展公告》显示,根据广州汇垠澳丰股权投资基金管理 有限公司(以下简称"汇垠澳丰")向北京首拓融汇投资有限公 司(以下简称"北京首拓")发送的《关于解除<合作协议>的函》, 《广州汇垠澳丰股权投资基金管理有限公司与北京首拓融汇投资 有限公司之合作协议》(以下简称"合作协议")自《关于解除< 合作协议>的函》发出之日起解除,你公司控制权存在变更的可 能。我部对此表示关注,请你公司就以下问题做出书面说明: 1.请你公司核实北京首拓是否认可上述合作协议解除事项。 2.请你公司结合合作协议的约定,严格对照《上市公司收购 管理办法》第八十四条规定,逐条分析合作协议解除后,汇垠澳 丰能否控制你公司,公司控制权的归属情况及认定依据。 3.请说明你公司及控股股东拟采取何种措施维持你公司控 1 5.你公司认为应予以说明的其他事项。 请你公司就上述问题做出书面说明,在 2023 年 8 月 23 日前 将有关说明材料报 ...
皓宸医疗:关于公司控制权可能发生变更的进展公告
2023-08-08 13:06
关于公司控制权可能发生变更的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 重要提示: 根据广州汇垠澳丰股权投资基金管理有限公司向北京首拓融汇投资有限公 司发送的《关于解除<合作协议>的函》,《广州汇垠澳丰股权投资基金管理有 限公司与北京首拓融汇投资有限公司之合作协议》(以下简称"合作协议") 自《关于解除<合作协议>的函》发出之日起解除。敬请广大投资者注意投资风 险。 一、前次权益变动基本情况 证券代码:002622 证券简称:皓宸医疗 公告编号:2023-033 皓宸医疗科技股份有限公司 皓宸医疗科技股份有限公司(以下简称"公司"或"上市公司")第一大股 东广州汇垠日丰投资合伙企业(有限合伙)(以下简称"汇垠日丰")之普通合 伙人及执行事务合伙人广州汇垠澳丰股权投资基金管理有限公司(以下简称"汇 垠澳丰")与北京首拓融汇投资有限公司(以下简称"北京首拓融汇")于 2020 年 2 月 10 日签署《广州汇垠澳丰股权投资基金管理有限公司与北京首拓融汇投 资有限公司之合作协议》。 根据合作协议约定,汇垠澳丰将根据北京首拓融汇的咨询意见及投资建议行 使 ...
皓宸医疗:皓宸医疗业绩说明会、路演活动信息
2023-05-23 12:11
| 投资者关系活动 | 分析师会议 □特定对象调研 □ | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | 其他 □ | | 参与单位名称及 | | | | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日(周一) 下午 2023 5 22 14:30~16:00 | | 地点 | 公司通过全景网"投资者关系互动平台"(https://ir.p5w.net) | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长、总经理(代)陆璐 | | 员姓名 | 2、副总经理、财务总监邓强 | | | 3、董事、副总经理、董事会秘书康超 | | | 1、请问对于横向并购的考虑是怎样的呢?有无目标地域或 | | | 者收购对象呢? | | | 尊敬的投资者,您好!未来公司将根据"广佛——珠三角 | | | ——大湾区"的发展路径稳步推进德伦品牌,并在全国其他地区 | | | 挑选当地运营不错的口腔连锁,待时机成熟后并入上市公司,同 | | | 时坚持并购后区域品牌不变、核心 ...
皓宸医疗:关于参加网上集体业绩说明会的公告
2023-05-12 10:47
为进一步加强与投资者的互动交流,皓宸医疗科技股份有限公司(以下简称 "公司")将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限公司 共同举办的"2023年吉林辖区上市公司网上集体业绩说明会",现将有关事项公 告如下: 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行,投资者可以登陆全景网"投资者关系互动平台"(http://ir.p5w.net)参 与公司业绩说明会,时间为2023年5月22日(星期一)14:30至16:00。 届时公司董事长/总经理(代)陆璐女士,副总经理、财务总监邓强先生, 副总经理、董事、董事会秘书康超先生将通过网络在线问答互动的形式,与投资 者就2022年经营业绩等投资者关注的问题进行交流。期间,公司高管将全程在线, 实时回答投资者的提问。投资者可于2022年5月19日(星期五)17:00前访问 https://ir.p5w.net/zj/,进入问题征集专题页面,欢迎广大投资者积极参与。 证券代码:002622 证券简称:皓宸医疗 公告编号:2023-024 皓宸医疗科技股份有限公司 关于参加网上集体业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的 ...
皓宸医疗(002622) - 2022 Q4 - 年度财报
2023-04-28 16:00
Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan in 2022, representing a year-over-year growth of 25%[19]. - The company's operating revenue for 2022 was ¥500,650,216.76, representing a 197.82% increase compared to ¥168,106,984.77 in 2021[22]. - The net profit attributable to shareholders was -¥256,788,671.99 in 2022, a decrease of 237.96% from -¥75,981,538.91 in 2021[23]. - The cash flow from operating activities increased by 75.56% to ¥32,245,101.11 in 2022, up from ¥18,367,226.36 in 2021[23]. - The basic earnings per share for 2022 was -¥0.3057, a decline of 237.79% from -¥0.0905 in 2021[23]. - The company reported a net profit attributable to shareholders of -¥256,788,671.99, a significant decrease of 237.96% year-on-year, primarily due to provisions for expected liabilities and goodwill impairment[49]. - The company reported a significant difference between net cash flow from operating activities and net profit due to provisions for litigation and accounting standards[69]. - The company reported a net profit margin of 12%, which is an improvement from 10% in the previous year[149]. - The actual net profit for 2022 was reported at CNY -44.46 million, indicating a significant shortfall compared to the commitment[162]. User Growth and Market Expansion - User data showed a growth in active users, reaching 2 million by the end of 2022, an increase of 40% compared to the previous year[19]. - User data showed a 30% increase in active users, reaching 2 million by the end of the fiscal year[116]. - The company is expanding its market presence, targeting an additional 100 clinics across China by the end of 2023[19]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market penetration by the end of the next fiscal year[116]. - The company is expanding its market presence, targeting an additional 10 provinces in China by the end of the next fiscal year[155]. Product Development and Innovation - New product development includes the launch of a cutting-edge dental service platform, expected to enhance service efficiency by 50%[19]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative medical technologies[150]. - The company is investing 200 million RMB in R&D for innovative technologies aimed at enhancing product efficiency and user experience[151]. - The company is focusing on expanding its product categories and improving market competitiveness through new product development and technology upgrades[62]. - The introduction of Insignia personalized orthodontic technology aims to enhance clinical treatment efficiency and precision[62]. Strategic Acquisitions and Investments - A strategic acquisition of Guangdong Delun Medical Group has been completed, enhancing the company's capabilities in dental services[19]. - A strategic acquisition of a local competitor was completed, expected to enhance operational efficiency and increase annual revenue by approximately 200 million RMB[116]. - The company plans to enhance its oral medical service quality management and control, ensuring standardized implementation[85]. - The company is exploring potential acquisitions to bolster its product portfolio, with a budget of up to 500 million RMB allocated for this purpose[149]. Financial Management and Governance - The board has decided not to distribute cash dividends for the fiscal year 2022, focusing on reinvestment for growth[4]. - The company has established a complete and independent financial accounting department, ensuring no shared bank accounts with shareholders[105]. - The company has a governance structure that complies with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange[97]. - The company has a dedicated investor relations management system to enhance communication and transparency with investors[103]. - The company has committed to strict adherence to its promises regarding avoiding competition and managing its subsidiaries[154]. Risks and Challenges - The company faces potential risks related to market fluctuations and regulatory changes, which may impact future performance[3]. - The company is addressing potential policy risks by closely monitoring regulatory trends in the oral medical industry[86]. - The company has recognized an impairment provision of CNY 18.20 million for goodwill related to Derun Medical, leaving a carrying amount of CNY 199.67 million[164]. Social Responsibility and Community Engagement - The company has actively engaged in over 1,000 free dental check-up events and oral health lectures, reaching more than 100,000 people during the reporting period[145]. - The company has focused on social responsibility by participating in community welfare activities and supporting local education and health initiatives[145]. - The company has implemented energy-saving measures by introducing advanced technologies and gradually phasing out high-energy-consuming equipment[145]. Research and Development - The company plans to invest 200 million yuan in R&D for new medical technologies over the next two years[19]. - R&D investment increased by 47.88% to ¥14,568,436.83, but the proportion of R&D investment to operating revenue decreased to 2.91% from 5.86%[65]. - The company is conducting research on the application of digital invisible orthodontics technology for the traction of impacted teeth in adults, aiming to enhance aesthetic treatment options[63]. Employee Management and Training - The total number of employees at the end of the reporting period is 1,487, with 567 being medical staff[131]. - The company has implemented a strict compensation management system, linking employee salaries to company performance[132]. - During the reporting period, the company organized 7 training sessions focused on industry operations and compliance[133].
皓宸医疗(002622) - 2023 Q1 - 季度财报
2023-04-28 16:00
Financial Performance - The company's operating revenue for Q1 2023 was ¥129,643,591.18, representing a 57.17% increase compared to ¥82,485,669.07 in the same period last year[4] - The net loss attributable to shareholders was ¥707,071.25, a 97.21% improvement from a net loss of ¥25,339,030.73 in the previous year[4] - The net cash flow from operating activities was ¥3,397,477.87, a significant turnaround from a negative cash flow of ¥32,253,006.95 in the same period last year, marking a 110.53% increase[4] - The company reported a net loss of CNY 228,901,186.14 for Q1 2023, compared to a loss of CNY 228,194,114.89 in the previous year[13] - The net profit for Q1 2023 was a loss of CNY 3,150,084.93, an improvement from a loss of CNY 36,395,477.46 in the same period last year[16] - The operating profit for Q1 2023 was a loss of CNY 3,105,393.10, significantly better than the loss of CNY 36,949,175.55 in Q1 2022[16] - The total comprehensive income for Q1 2023 was a loss of CNY 3,182,717.04, compared to a loss of CNY 36,704,772.00 in Q1 2022[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,672,547,396.21, reflecting a 1.21% increase from ¥1,652,618,278.43 at the end of the previous year[4] - Cash and cash equivalents at the end of Q1 2023 were CNY 151,850,814.49, an increase from CNY 120,113,833.90 at the beginning of the year[11] - Total assets as of March 31, 2023, were CNY 1,672,547,396.21, compared to CNY 1,635,408,931.74 at the beginning of the year[13] - Total liabilities increased to CNY 1,106,976,510.32 from CNY 1,066,655,328.80 at the start of the year[13] - The company's equity attributable to shareholders was CNY 571,761,045.51, a slight decrease from CNY 572,500,748.87 at the beginning of the year[13] Cash Flow and Management - The cash received from sales of goods and services increased by 52.5%, totaling an increase of ¥46,340,000 compared to the previous year[6] - The company received tax refunds amounting to CNY 1,355,460.09 in Q1 2023, compared to CNY 807,080.32 in Q1 2022, indicating better cash flow management[19] - The company incurred financial expenses of CNY 8,273,195.31 in Q1 2023, down from CNY 11,223,616.88 in Q1 2022, reflecting improved cost management[16] Research and Development - The company reported a decrease in research and development expenses by 51.77%, amounting to a reduction of ¥720,000 compared to the previous year[6] - Research and development expenses decreased to CNY 669,850.77 in Q1 2023 from CNY 1,388,879.00 in Q1 2022, indicating a reduction in R&D investment[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 51,221, with no preferred shareholders[8] - The company's basic earnings per share improved by 97.35%, reaching -¥0.0008 compared to -¥0.0302 in the same period last year[4] - The basic and diluted earnings per share for Q1 2023 were both -0.0008, an improvement from -0.0302 in Q1 2022[16] Future Plans - The company plans to focus on expanding its market presence and developing new technologies in the upcoming quarters[12]
皓宸医疗(002622) - 2016年2月29日投资者关系活动记录表
2022-12-06 11:28
证券代码:002622 证券简称:永大集团 吉林永大集团股份有限公司 投资者关系活动记录表 编号:001 | --- | --- | --- | |-----------------------------|-----------------------------------|------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 其他 | | 参与单位名称及 | | 国泰君安:孔祥、张为、张天阳、周津宇、李树林 | | 人员姓名 | 东北证券:张经纬 兴业证券:段涛涛 | | | | | | | 时间 | 2016 年 02 月 | 29 日 | | 地点 | 吉林永大集团股份有限公司 | | | 上市公司接待人 | | 副总经理、董事会秘书 黄佳慧 | | 员姓名 | 证券事务代表 郑颖 | | | 投资者关系活动 主要内容介绍 | 一、 | 公司目前总体经营管理 ...
皓宸医疗(002622) - 2022 Q2 - 季度财报
2022-08-30 16:00
Financial Performance - The company's operating revenue for the first half of 2022 was ¥211,861,084.40, representing a 331.50% increase compared to ¥49,098,637.57 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was -¥30,559,032.20, a decrease of 429.97% from ¥9,261,137.11 in the previous year[19]. - The net cash flow from operating activities was -¥36,173,487.44, down 762.30% from ¥5,461,770.60 in the same period last year[19]. - The total assets at the end of the reporting period were ¥1,707,270,734.76, a decrease of 4.74% from ¥1,792,171,860.35 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were ¥828,063,896.24, down 3.61% from ¥859,104,421.04 at the end of the previous year[19]. - The basic earnings per share were -¥0.0364, a decline of 430.91% compared to ¥0.0110 in the same period last year[19]. - The diluted earnings per share were also -¥0.0364, reflecting the same percentage decline as basic earnings per share[19]. - The weighted average return on net assets was -3.62%, a decrease of 4.64% from 1.02% in the previous year[19]. - The company reported a significant increase in revenue, reaching ¥211,861,084.40, a 331.50% increase compared to ¥49,098,637.57 in the previous year, primarily due to the acquisition of Delun Medical[40]. - Operating costs rose to ¥131,603,797.34, reflecting a 427.79% increase from ¥24,935,067.59, driven by the expanded revenue scale following the acquisition[40]. - Sales expenses surged to ¥49,886,520.74, marking a 1,966.26% increase from ¥2,414,335.47, also attributed to the acquisition of Delun Medical[40]. - The company reported a net profit loss of CNY 44,311,085.97 for the first half of 2022, compared to a net profit of CNY 9,261,137.11 in the same period of 2021[134]. - The total profit loss amounted to CNY 46,471,448.90, a stark contrast to the profit of CNY 9,650,546.99 reported in the first half of 2021[134]. Business Operations - The company has established a dual business operation model focusing on "oral medical services + industrial manufacturing" after transferring 100% equity of its subsidiary, Zhiyong Technology, to Jiangxi Yuru Data Technology Development Co., Ltd., retaining 45% equity[27]. - The dental service segment has expanded its operations to cover Guangzhou and Foshan, with a strong regional brand influence, and aims to enhance its market penetration through the opening of new clinics[28][32]. - The company has invested in children's dental specialty clinics in Yuexiu and Panyu districts, which are expected to become new growth points for performance, with one recognized as a "Guangzhou Children's Oral Health Science Base"[33]. - The digitalization of dental services has been a key focus, with over 90% usage rate of digital guides in dental implant procedures, positioning the company as a leader in the industry[30]. - The company operates 1 dental hospital and 24 direct chain clinics, covering over 24,000 square meters and equipped with more than 350 dental chairs, making it one of the largest dental service providers in South China[30]. - The company has completed the opening of four new dental clinics during the reporting period, with plans for further expansion in the Guangzhou and Foshan areas[32]. - The electrical business segment, through its subsidiary Jilin Yongda Electric Switch Co., Ltd., has developed a comprehensive marketing network across more than 20 provinces, providing integrated pre-sale, in-sale, and after-sale services[33]. - The company is committed to the digital transformation of the manufacturing sector, aligning with national strategies to enhance the competitiveness and quality of the manufacturing industry[27]. - The dental service industry is expected to grow significantly due to increasing public awareness of oral health and rising disposable income, supported by national health policies[29]. - The company has established a "1+N" business model for dental services, integrating flagship and community clinics to enhance service delivery and patient experience[31]. Financial Position - Cash and cash equivalents at the end of the reporting period were ¥153,440,265.83, down from ¥192,343,847.31 at the end of the previous year[49]. - Long-term equity investments increased by 2.22% to ¥574,535,179.04, representing 33.65% of total assets[49]. - Short-term borrowings decreased to ¥120,348,333.00, a reduction of 0.28% from the previous year[49]. - The total restricted assets amount to ¥804,929,053.64, including cash deposits of ¥1,800,049.79, receivables of ¥22,700,000.00, and long-term equity investments of ¥574,282,349.21 due to litigation freezes and pledges[52]. - The company has no significant equity or non-equity investments during the reporting period[53]. - The company reported no derivative investments during the reporting period[55]. - The company has not undergone any bankruptcy restructuring or significant contract issues during the reporting period[85][97]. - The total liabilities decreased to CNY 873,275,405.30 from CNY 913,383,952.32, marking a reduction of about 4.4%[127]. - The total equity attributable to shareholders decreased to CNY 828,063,896.24 from CNY 859,104,421.04, a decline of approximately 3.6%[127]. Risk Management - The report highlights potential risks and uncertainties that may affect future performance, urging investors to be cautious[4]. - The company faces regulatory risks related to the dental implant market, with potential impacts from centralized procurement policies[62]. - The company is committed to enhancing its operational management and internal controls to address challenges from business expansion in the dental medical service sector[63]. - The company aims to improve talent retention strategies to mitigate risks associated with the loss of specialized medical personnel[64]. - The company expects that the ongoing impact of the COVID-19 pandemic will continue to affect its operating performance in the future[66]. - The company has established a referral mechanism to mitigate the impact of pandemic-related service interruptions, leveraging its multiple clinic locations[66]. - The company plans to maintain strict risk control and scientific investment decision-making processes to ensure long-term development[68]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,795[111]. - Guangzhou Huiyin Rife Investment Partnership holds 23.81% of shares, totaling 200,000,000 shares[111]. - Shaanxi International Trust Company holds 3.84% of shares, totaling 32,263,200 shares[111]. - The total number of limited sale condition shares is 24,750, accounting for 0.00% of the total[109]. - The total number of unrestricted sale condition shares is 839,975,250, accounting for 100.00% of the total[109]. - There were no changes in the number of shares held by major shareholders during the reporting period[111]. - The company did not implement any share buyback or reduction during the reporting period[110]. - There were no new share issuances or transfers reported[110]. - The company has not disclosed any impacts on financial metrics due to share changes[110]. Corporate Governance - The company disclosed the resignation of the vice chairman and general manager, along with the election of a new chairman and appointment of a new general manager[104]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[82]. - There were no significant lawsuits or arbitration matters reported during the period, with a total of 4,634.88 thousand yuan involved in minor cases[87]. - The company has not engaged in any major related party transactions during the reporting period[89]. - The company has not experienced any violations regarding external guarantees during the reporting period[83]. - The company maintains a good integrity status for both itself and its major shareholders during the reporting period[88]. Social Responsibility - The company actively engages in social responsibility, focusing on product safety, environmental protection, and energy conservation, leading to improved product quality and enhanced industry competitiveness[78]. - Since the outbreak of the pandemic, the company has organized 72 batches of over 430 medical personnel to support large-scale nucleic acid testing and vaccination efforts in Guangzhou and Foshan, contributing to public health[79]. - The company emphasizes energy conservation by introducing advanced technologies and gradually phasing out high-energy-consuming equipment[78]. - The company has established a comprehensive oral healthcare service system under its subsidiary, aiming to meet the needs of dental patients and support the "Healthy China" initiative[78]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters[146]. - The management provided a revenue guidance for the second half of 2022, expecting a growth of 5% to 10% compared to the first half of the year[147]. - Future performance guidance remains optimistic, with expectations of revenue growth driven by new technologies and market strategies[146].
皓宸医疗(002622) - 2022 Q1 - 季度财报
2022-04-28 16:00
Financial Performance - The company's revenue for Q1 2022 was ¥82,485,669.07, representing a 395.85% increase compared to ¥16,635,191.36 in the same period last year[3] - The net profit attributable to shareholders was -¥25,339,030.73, a decrease of 693.98% from -¥3,191,400.03 year-on-year[3] - The total operating revenue for the first quarter of 2022 was ¥82,485,669.07, a significant increase from ¥16,635,191.36 in the same period last year, representing a growth of 394.4%[18] - The net loss for the first quarter was ¥36,395,477.46, compared to a net loss of ¥3,191,400.03 in the previous year, reflecting a deterioration in performance[20] - The total comprehensive loss for the first quarter was ¥36,704,772.00, compared to a loss of ¥7,329,294.08 in the previous year[21] - Basic and diluted earnings per share were both reported at -¥0.0302, a decline from -¥0.0038 in the same quarter last year[21] Cash Flow - The net cash flow from operating activities was -¥32,253,006.95, a decline of 892.49% compared to ¥4,069,851.03 in the previous year[3] - The cash flow from operating activities showed a net outflow of ¥32,253,006.95, contrasting with a net inflow of ¥4,069,851.03 in the same quarter last year[22] - The company reported a net cash inflow from investing activities of ¥54,470,751.65, primarily from the recovery of investments totaling ¥55,000,000.00[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,719,382,737.43, down 4.06% from ¥1,792,171,860.35 at the end of the previous year[3] - Total current assets decreased from 418,800,603.81 to 357,708,188.53, a decline of approximately 14.6%[16] - Cash and cash equivalents decreased from 192,343,847.31 to 186,794,081.84, a decrease of about 2.9%[15] - Accounts receivable decreased from 47,221,817.21 to 42,991,129.08, a decline of approximately 9.4%[16] - The company's total liabilities decreased by ¥23,000,000, reflecting a reduction in debt obligations during the reporting period[9] - Total liabilities decreased from 913,383,952.32 to 877,299,601.40, a reduction of about 4.0%[17] - The company's equity attributable to shareholders decreased from 859,104,421.04 to 833,456,095.77, a decrease of about 3.0%[17] - The company’s total liabilities and equity decreased from ¥1,792,171,860.35 to ¥1,719,382,737.43, indicating a reduction in financial leverage[18] Expenses - The company reported an increase in sales expenses by ¥19,830,000, primarily due to the acquisition of 51% of Delun Medical and the expansion into the dental medical sector[7] - The company’s management expenses increased by ¥27,770,000, also attributed to the acquisition and related business expansion[7] - The total operating costs for the first quarter were ¥124,438,676.52, up from ¥30,562,144.94, indicating an increase of 307.5%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 57,916[12] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of shares, totaling 200,000,000 shares[12] - The number of shares held by the top ten unrestricted shareholders totals 200,000,000 and 32,263,200 shares respectively[12] Other Financial Information - The company received government subsidies amounting to ¥113,105.57, contributing to its financial performance[5] - The company reported a significant reduction in other receivables from 95,402,811.61 to 41,848,819.04, a decline of approximately 56.1%[16] - The company has not undergone an audit for the first quarter report[24]
皓宸医疗(002622) - 2021 Q4 - 年度财报
2022-04-28 16:00
Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a year-over-year growth of 20%[165]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[161]. - The company achieved a total revenue of ¥168,106,984.77 in 2021, representing a 47.02% increase compared to ¥114,345,046.98 in 2020[51]. - The company's operating revenue for 2021 was ¥168,106,984.77, representing a 47.02% increase compared to ¥114,345,046.98 in 2020[21]. - The electrical switch industry contributed ¥95,402,981.23, accounting for 56.75% of total revenue, with a year-on-year growth of 28.38%[51]. - The newly acquired dental medical service sector generated ¥49,181,650.06, making up 29.26% of total revenue, marking its first contribution since the acquisition[51]. - The software development sector saw a decline in revenue to ¥21,445,305.76, down 43.19% from the previous year[52]. - The company reported a net profit margin of 12% for 2021, an increase from 10% in the previous year, indicating improved profitability[161]. - The company reported a net profit attributable to shareholders was -¥75,981,538.91, an improvement of 74.43% from -¥297,124,345.16 in the previous year[21]. Acquisitions and Business Expansion - The company completed the acquisition of controlling interest in Delun Medical on November 18, 2021, making it a subsidiary[18]. - The company completed the acquisition of Guangzhou Delun Medical Group in November 2021, contributing ¥49,180,000 to the fourth quarter's revenue[25]. - The company completed the acquisition of 51% of Delun Medical in November 2021, marking its entry into the dental medical service industry[46]. - The company acquired 51% of Guangdong Delun Medical Group for a total of 245 million CNY, enhancing its presence in the dental medical service industry[92]. - The company plans to optimize the profitability and sustainable development of Delun Medical under its strategic management[93]. - The company aims to actively pursue mergers and acquisitions in the dental medical field to enhance its service capabilities and achieve synergistic effects[95]. Operational Efficiency and Cost Management - The company is focusing on enhancing its internal control and governance to improve operational efficiency and profitability[48]. - The company has implemented strict cost management measures to optimize its operational efficiency and control expenses[48]. - The company aims to reduce operational costs by 10% in 2022 through efficiency improvements and process optimization[157]. - The management team emphasized a commitment to improving operational efficiency, targeting a 5% reduction in costs over the next year[123]. - The company aims to reduce operational costs by 15% through efficiency improvements and process optimization in the upcoming year[165]. Market Trends and Industry Insights - The oral health industry is experiencing rapid growth, supported by national health policies aimed at improving public oral health awareness and services[34]. - The dental medical service industry is experiencing rapid growth, supported by favorable policies and increasing demand for oral health services[48]. - The oral health service market in China reached a scale of 103 billion yuan in 2019, with a year-on-year growth of 7.29%, and is expected to reach 124 billion yuan by 2021[37]. - The oral health awareness among the Chinese population has improved, with over 84% of citizens holding a positive attitude towards oral health[36]. Governance and Compliance - The company has established a transparent information disclosure system to enhance communication with investors[103]. - The company has not engaged in any investor communication activities during the reporting period[100]. - The company has held 4 shareholder meetings and 8 board meetings, ensuring compliance with governance regulations[102]. - The company maintains independence from its controlling shareholders in business, personnel, assets, and financial aspects[105]. - The company has committed to strict compliance with laws and regulations, ensuring no major breaches of trust or legal issues[164]. Research and Development - Research and development expenses increased by 30%, totaling 150 million RMB, to support new technology initiatives[121]. - The company has implemented a performance management system to link employee compensation with company performance[138]. - The number of R&D personnel decreased by 9.09% from 77 in 2020 to 70 in 2021, with the proportion of R&D personnel dropping from 19.00% to 5.00%[68]. - R&D investment increased by 23.20% from ¥7,996,687.44 in 2020 to ¥9,851,754.19 in 2021, while the proportion of R&D investment to operating revenue decreased from 6.99% to 5.86%[68]. Financial Position and Assets - The company’s total assets and liabilities as of December 31, 2021, were reported, reflecting its financial position[18]. - The total assets at the end of 2021 were ¥1,792,171,860.35, a 33.69% increase from ¥1,340,539,193.47 at the end of 2020[21]. - Cash and cash equivalents decreased to ¥192,343,847.31, accounting for 10.73% of total assets, down from 14.50%[76]. - The company reported an asset impairment provision of ¥16,630,900 and a credit impairment loss of ¥619,200 during the reporting period[72]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,365, with 1,344 from major subsidiaries[136]. - The company has 46 employees with a master's degree or above, and 1,062 with a college degree or below[137]. - The company has a diverse board with members holding various professional backgrounds, including finance, law, and healthcare[113][114][115][116]. - The company has maintained a stable management team with no significant turnover in key positions since 2020[110]. Social Responsibility and Sustainability - The company actively engages in social responsibility initiatives, including energy conservation, environmental protection, and employee rights protection[152]. - The company has committed to sustainability initiatives, aiming for a 50% reduction in carbon emissions by 2025[168]. - The company has implemented measures to improve product quality and safety, as well as to enhance production safety and reduce energy consumption[152]. Risks and Challenges - The company’s future operational plans and targets are subject to market conditions and uncertainties, highlighting investment risks[4]. - The company acknowledges potential policy risks related to dental implant procurement policies that may impact service prices and market demand[97]. - The company is focused on enhancing operational management and internal controls to address challenges arising from business expansion in the dental medical sector[98].